Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ty Gould

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Frontiers in Pharmacology|August 15, 2014
Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchTove Tuntland, Brian Ethell, Takatoshi Kosaka, et al.
Journal of Medicinal Chemistry|July 25, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrasesMichael D Shultz, Dyuti Majumdar, Donovan N Chin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Tumor targeting by an aptamerBrian J Hicke, Andrew W Stephens, Ty Gould, et al.
Molecular and Cellular Biology|October 31, 2012
Defective autophagy and mTORC1 signaling in myotubularin null miceKristina M Fetalvero, Yenyen Yu, Margaret Goetschkes, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 InhibitorsQian Zhao, James R Manning, James Sutton, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorYoung Shin Cho, Julian R Levell, Gang Liu, et al.
Nature Chemical Biology|November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathwayJürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Frontiers in Pharmacology|August 15, 2014
Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical ResearchTove Tuntland, Brian Ethell, Takatoshi Kosaka, et al.
Journal of Medicinal Chemistry|July 25, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrasesMichael D Shultz, Dyuti Majumdar, Donovan N Chin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Tumor targeting by an aptamerBrian J Hicke, Andrew W Stephens, Ty Gould, et al.
Molecular and Cellular Biology|October 31, 2012
Defective autophagy and mTORC1 signaling in myotubularin null miceKristina M Fetalvero, Yenyen Yu, Margaret Goetschkes, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 InhibitorsQian Zhao, James R Manning, James Sutton, et al.
ACS Medicinal Chemistry Letters|October 24, 2017
Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 InhibitorYoung Shin Cho, Julian R Levell, Gang Liu, et al.
Nature Chemical Biology|November 4, 2016
Small-molecule factor D inhibitors targeting the alternative complement pathwayJürgen Maibaum, Sha-Mei Liao, Anna Vulpetti, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Pageof 1